WO2021010745A3 - 에티오나마이드를 이용한 줄기세포의 효능 강화방법 - Google Patents

에티오나마이드를 이용한 줄기세포의 효능 강화방법 Download PDF

Info

Publication number
WO2021010745A3
WO2021010745A3 PCT/KR2020/009312 KR2020009312W WO2021010745A3 WO 2021010745 A3 WO2021010745 A3 WO 2021010745A3 KR 2020009312 W KR2020009312 W KR 2020009312W WO 2021010745 A3 WO2021010745 A3 WO 2021010745A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cell
ethionamide
efficacy
enhancing
enhancing efficacy
Prior art date
Application number
PCT/KR2020/009312
Other languages
English (en)
French (fr)
Other versions
WO2021010745A2 (ko
Inventor
나덕렬
장종욱
손효진
Original Assignee
사회복지법인 삼성생명공익재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200086685A external-priority patent/KR102556520B1/ko
Application filed by 사회복지법인 삼성생명공익재단 filed Critical 사회복지법인 삼성생명공익재단
Priority to CN202080051467.2A priority Critical patent/CN114127265A/zh
Priority to EP20839615.0A priority patent/EP4001400A4/en
Priority to US17/054,939 priority patent/US11946070B2/en
Priority to JP2022502529A priority patent/JP2022541476A/ja
Publication of WO2021010745A2 publication Critical patent/WO2021010745A2/ko
Publication of WO2021010745A3 publication Critical patent/WO2021010745A3/ko
Priority to JP2023178747A priority patent/JP2023174825A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은, 에티오나마이드(ethionamide)를 포함하는 줄기세포의 효능 강화용 배지 조성물, 상기 배지 조성물에서 줄기세포를 배양하는 단계를 포함하는 줄기세포의 효능 강화방법 및 효능이 강화된 줄기세포의 제조방법, 상기 방법에 의해 제조된 줄기세포 및 이의 용도에 관한 것이다. 본 발명에 따르면 중간엽 줄기세포에 에티오나마이드를 처리하는 간단한 과정으로 중간엽 줄기세포의 항염증 효과 및 근거리분비 인자들의 발현량을 효과적으로 증진시킬 수 있으며, 이러한 방법에 의해 얻어진 줄기세포는 염증성 질환 또는 퇴행성 뇌질환의 예방 또는 치료용도로써 유용하게 이용될 수 있을 것이다.
PCT/KR2020/009312 2019-07-15 2020-07-15 에티오나마이드를 이용한 줄기세포의 효능 강화방법 WO2021010745A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202080051467.2A CN114127265A (zh) 2019-07-15 2020-07-15 通过使用乙硫异烟胺增强干细胞功效的方法
EP20839615.0A EP4001400A4 (en) 2019-07-15 2020-07-15 METHOD OF ENHANCING THE EFFICIENCY OF A STEM CELL USING ETHIONAMIDE
US17/054,939 US11946070B2 (en) 2019-07-15 2020-07-15 Method of reinforcing efficacy of stem cells using ethionamide
JP2022502529A JP2022541476A (ja) 2019-07-15 2020-07-15 エチオナミドを用いた幹細胞の効能強化方法
JP2023178747A JP2023174825A (ja) 2019-07-15 2023-10-17 エチオナミドを用いた幹細胞の効能強化方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2019-0085137 2019-07-15
KR20190085137 2019-07-15
KR1020200086685A KR102556520B1 (ko) 2019-07-15 2020-07-14 에티오나마이드를 이용한 줄기세포의 효능 강화방법
KR10-2020-0086685 2020-07-14

Publications (2)

Publication Number Publication Date
WO2021010745A2 WO2021010745A2 (ko) 2021-01-21
WO2021010745A3 true WO2021010745A3 (ko) 2021-03-11

Family

ID=74210954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/009312 WO2021010745A2 (ko) 2019-07-15 2020-07-15 에티오나마이드를 이용한 줄기세포의 효능 강화방법

Country Status (1)

Country Link
WO (1) WO2021010745A2 (ko)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190047880A (ko) * 2017-10-30 2019-05-09 사회복지법인 삼성생명공익재단 에티오나마이드를 이용한 줄기세포 이동성 향상 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190047880A (ko) * 2017-10-30 2019-05-09 사회복지법인 삼성생명공익재단 에티오나마이드를 이용한 줄기세포 이동성 향상 방법

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARHANPURKAR-NAIK AMRUTA, MHASKE SUHAS T., POTE SATISH T., SINGH KANUPRIYA, WANI MOHAN R.: "Interleukin-3 enhances the migration of human mesenchymal stem cells by regulating expression of CXCR4", STEM CELL RESEARCH & THERAPY, vol. 8, no. 1, 1 December 2017 (2017-12-01), pages 1 - 15, XP055788338, DOI: 10.1186/s13287-017-0618-y *
LIU XINGXING; ZUO DONGMEI; FAN HENG; TANG QING; SHOU ZHEXING; CAO DAN; ZOU ZHOU: "Over-expression of CXCR4 on mesenchymal stem cells protect against experimental colitis via immunomodulatory functions in impaired tissue", JOURNAL OF MOLECULAR HISTOLOGY, SPRINGER-VERLAG, DORDRECHT, NL, vol. 45, no. 2, 12 October 2013 (2013-10-12), NL, pages 181 - 193, XP035347166, ISSN: 1567-2379, DOI: 10.1007/s10735-013-9541-4 *
WEI JI-NAN, CAI FENG, WANG FENG, WU XIAO-TAO, LIU LEI, HONG XIN, TANG WEN-HAO: "Transplantation of CXCR4 Overexpressed Mesenchymal Stem Cells Augments Regeneration in Degenerated Intervertebral Discs", DNA AND CELL BIOLOGY, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 35, no. 5, 1 May 2016 (2016-05-01), US, pages 241 - 248, XP055788342, ISSN: 1044-5498, DOI: 10.1089/dna.2015.3118 *
ZHANG, D. FAN, G.C. ZHOU, X. ZHAO, T. PASHA, Z. XU, M. ZHU, Y. ASHRAF, M. WANG, Y.: "Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY., ACADEMIC PRESS, GB, vol. 44, no. 2, 16 January 2008 (2008-01-16), GB, pages 281 - 292, XP022481145, ISSN: 0022-2828 *
ZHAOKANG CHENG, LAILIANG OU, XIN ZHOU, FEI LI, XIAOHUA JIA, YINGUO ZHANG, XIAOLEI LIU, YUMING LI, CHRISTOPHER A WARD, LUIS G MELO,: "Targeted Migration of Mesenchymal Stem Cells Modified With CXCR4 Gene to Infarcted Myocardium Improves Cardiac Performance", MOLECULAR THERAPY, NO LONGER PUBLISHED BY ELSEVIER, vol. 16, no. 3, 1 March 2008 (2008-03-01), pages 571 - 579, XP055099886, ISSN: 15250016, DOI: 10.1038/sj.mt.6300374 *

Also Published As

Publication number Publication date
WO2021010745A2 (ko) 2021-01-21

Similar Documents

Publication Publication Date Title
AR053395A1 (es) Procedimiento novedoso para la reduccion enzimatica de acrilamida en productos alimenticios
NZ620113A (en) Enterobacter sp. 638 and methods of use thereof
WO2016073990A3 (en) Methods for improving crispr/cas-mediated genome-editing
GB2452667A (en) Efficient generation of neural progenitors, neurons and dopaminergic neurons from human embryonic stem cells
WO2006071802A3 (en) Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
WO2009135685A3 (de) Vorrichtung und verfahren zum tempern von gegenständen in einer behandlungskammer
MA46140A (fr) Facteur de transcription nterf241 et ses procédés d'utilisation
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
WO2016081032A3 (en) Mesenchymal stem cells derived from induced pluripotent stem cells
JP2018508231A5 (ko)
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
WO2016142219A8 (de) Leuchtstoffpartikel mit einer schutzschicht und verfahren zur herstellung der leuchtstoffpartikel mit der schutzschicht
WO2015056258A3 (en) Method of obtaining terminally differentiated neuronal lineages and uses thereof
WO2019066549A3 (ko) 망막 기능장애 질환 치료를 위한 유전자 조작
WO2015064805A8 (ko) 중간엽 줄기세포로부터 유도된 만능 줄기세포를 이용하여 연골세포로 분화시키는 방법
MX2017013735A (es) Proceso para preparar extracto de chicharos.
MX2019009514A (es) Sustrato de lamina de acero inoxidable para separadores de celdas de combustible y metodo de produccion del mismo.
WO2020081742A3 (en) Live biotherapeutics to treat and prevent lung conditions
MX2018015234A (es) Métodos para mejorar la transformación genética de sorgo.
WO2021010745A3 (ko) 에티오나마이드를 이용한 줄기세포의 효능 강화방법
WO2017044968A3 (en) Methods for application of biochar
WO2021207282A3 (en) Lyophilized mesenchymal stem cell derived secretome and uses thereof
WO2018158542A8 (fr) Cellules souches mesenchymateuses issues de la gelée de wharton pour le traitement du sepsis
WO2015087637A8 (en) Composite particles comprising a metal-doped inorganic uv filter, and compositions containing them
WO2018026212A3 (ko) 섬유증 질환 모델의 제조방법 및 섬유증 질환 모델의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20839615

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2022502529

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020839615

Country of ref document: EP

Effective date: 20220215